Literature DB >> 2418935

Malignant melanoma. Inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate.

W A Cassel, K M Weidenheim, W G Campbell, D R Murray.   

Abstract

Five patients with advanced malignant melanoma, treated with viral oncolysate, had solitary central nervous system metastases that were removed surgically. Histologic examination revealed striking and significant mononuclear inflammatory cell infiltrates, consisting of a mean of 60% plasma cells and a lesser proportion of lymphocytes at the edges of the lesions, within their supporting fibrovascular trabeculae, and among the tumor cells. Comparable inflammatory changes were not found in solitary metastatic malignant melanomas removed surgically from the brains of 19 patients not treated with viral oncolysate. Similarly, multiple metastatic malignant melanomas obtained postmortem from the brains of 12 patients not treated with viral oncolysate showed minimal inflammatory responses. Ultrastructural examination of material from a single treated patient revealed morphologic abnormalities of the blood-brain barrier, changes that were perhaps conducive to infiltration of the neoplasm by inflammatory cells. The authors suggest that administration of viral oncolysate enhances the inflammatory cell response to metastatic malignant melanoma in the brain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418935     DOI: 10.1002/1097-0142(19860401)57:7<1302::aid-cncr2820570709>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Long-term survival after removal of primary intracranial malignant melanoma. Case report.

Authors:  H Nakagawa; T Hayakawa; K Niiyama; Y Nii; T Yoshimine; S Mori
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma.

Authors:  P Hersey
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

4.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

5.  Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

Authors:  J H Sampson; G E Archer; D M Ashley; H E Fuchs; L P Hale; G Dranoff; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

6.  Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.

Authors:  Ozge Gumusay; Ugur Coskun; Tülay Akman; Ahmet Siyar Ekinci; Muharrem Kocar; Ozlem Balvan Erceleb; Ozan Yazıcı; Mehmet Ali Kaplan; Veli Berk; Bulent Cetin; Burcu Yapar Taskoylu; Ayhan Yildiz; Gamze Goksel; Ahmet Alacacioglu; Umut Demirci; Efnan Algin; Mukremin Uysal; Ilhan Oztop; Berna Oksuzoglu; Faysal Dane; Mahmut Gumus; Suleyman Buyukberber
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-29       Impact factor: 4.553

Review 7.  Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.

Authors:  Dmitriy Zamarin; Sari Pesonen
Journal:  Hum Gene Ther       Date:  2015-08       Impact factor: 5.695

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.